JENA, Germany, April 30, 2025 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focused on developing anti-inflammatory treatments by modulating the complement system, announced today that its first quarter 2025 financial and operational results will be released on May 7, 2025, before the market opens. There will be no conference call held.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company dedicated to creating anti-inflammatory therapies using its exclusive anti-C5a and anti-C5aR technologies. The company aims to discover, develop, and market highly effective and specific inhibitors targeting the complement activation factor C5a and its receptor C5aR. C5a is a potent inflammatory mediator that contributes to the advancement of various inflammatory diseases. Vilobelimab, InflaRx’s leading product candidate, is a first-in-class, intravenously administered, anti-C5a monoclonal antibody that selectively binds to free C5a. It has shown disease-modifying clinical activity and good tolerability in several clinical trials across different indications. InflaRx is also working on INF904, an orally available, small molecule inhibitor of the C5a receptor. Founded in 2007, InflaRx has offices and subsidiaries in Jena and Munich, Germany, and Ann Arbor, MI, USA. For more details, please visit www.inflarx.com.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are fully owned subsidiaries of InflaRx N.V. (collectively, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: |
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. All statements that do not relate to historical facts are considered forward-looking statements. These statements are often identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” among other similar expressions. Forward-looking statements are present in various sections of this release and may include statements about our intentions, beliefs, projections, outlook, analyses, current expectations, and the risks, uncertainties, and other factors detailed under the headings “Risk Factors” and “Cautionary statement regarding forward looking statements” in our filings with the U.S. Securities and Exchange Commission. These statements are valid only as of the date of this press release and are subject to known and unknown risks, uncertainties, and other significant factors that could cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these statements. Due to these risks, uncertainties, and other factors, you should not rely excessively on these forward-looking statements. We do not undertake any obligation to update these statements, even if new information becomes available in the future, except as required by law.
